RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced the closing of its previously announced underwritten public offering, with total gross proceeds of approximately $15.0 million, which includes the full exercise of the underwriter’s over-allotment option to purchase additional shares, prior to deducting underwriting discounts and commissions and offering expenses payable by TransEnterix.
A total of 42,857,142 shares of common stock were issued in the offering, including the full exercise of the over-allotment option, at a public offering price of $0.35 per share, with total net proceeds of approximately $13.7 million. The Company currently intends to use the net proceeds of this offering for general corporate purposes, including working capital.
Ladenburg Thalmann & Co. Inc. acted as sole book-running manager in connection with the offering.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
A shelf registration statement relating to the shares of Common Stock being sold in this offering was previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 31, 2020 and was declared effective on February 10, 2020.
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
At TransEnterix, Inc., we are digitizing the interface between the surgeon and the patient to improve minimally invasive surgery (MIS) through a new category of care called Digital Laparoscopy. Digitizing the interface enables the use of advanced capabilities like augmented intelligence, connectivity and robotics in laparoscopy, and allows us to address the current clinical, cognitive and economic shortcomings in surgery. The Senhance® Surgical System brings the benefits of Digital Laparoscopy to patients around the world while staying true to the principles of value-based healthcare.